Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging
Authors
Keywords
-
Journal
MOLECULES
Volume 20, Issue 2, Pages 2081-2099
Publisher
MDPI AG
Online
2015-01-27
DOI
10.3390/molecules20022081
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imaging Atherosclerotic Plaque Inflammation via Folate Receptor Targeting Using a Novel 18 F-Folate Radiotracer
- (2018) Adrienne Müller et al. Molecular Imaging
- Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules
- (2014) Adrienne Müller et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
- (2014) Koen Jansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability
- (2014) Adrienne Müller et al. NUCLEAR MEDICINE AND BIOLOGY
- Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity
- (2014) Thomas Vogl et al. Nature Communications
- Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients
- (2013) Mercedes Herrera et al. CANCER SCIENCE
- Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase
- (2013) Sarah E. Poplawski et al. JOURNAL OF MEDICINAL CHEMISTRY
- In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE-/- Mice Using VCAM-1-Specific, 99mTc-Labeled Peptidic Sequences
- (2013) J. Dimastromatteo et al. JOURNAL OF NUCLEAR MEDICINE
- Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold
- (2013) Koen Jansen et al. ACS Medicinal Chemistry Letters
- Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein- and Heme Oxygenase-1
- (2013) J. N. Arnold et al. Cancer Immunology Research
- Fibroblast activation protein
- (2012) Rui Liu et al. CANCER BIOLOGY & THERAPY
- Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies
- (2012) E. Fischer et al. CLINICAL CANCER RESEARCH
- Molecular Imaging in Atherosclerosis: FDG PET
- (2012) David Rosenbaum et al. Current Atherosclerosis Reports
- Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque
- (2012) P. G. Camici et al. EUROPEAN HEART JOURNAL
- Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata
- (2011) Chad E. Brokopp et al. EUROPEAN HEART JOURNAL
- Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography
- (2011) O. Gaemperli et al. EUROPEAN HEART JOURNAL
- Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors
- (2011) Lawrence J. Milo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stabilisation of atherosclerotic plaques
- (2011) Jacob Fog Bentzon et al. THROMBOSIS AND HAEMOSTASIS
- Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
- (2009) Robert M Eager et al. BMC CANCER
- Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
- (2009) R.M. Eager et al. CLINICAL ONCOLOGY
- Critical Cap Thickness and Rupture in Symptomatic Carotid Plaques
- (2008) Jessica N. Redgrave et al. STROKE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started